A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Inclusion Criteria:

   - Have a histological or cytological diagnosis of malignant solid neoplasm requiring
   systemic chemotherapy.

   - Age ≥18 years.

   - ECOG performance status 0-1.

   - Adequate organ function.

   - Adequate hematological function.

   - Have the ability to understand the requirements of the study, provide written informed
   consent, and comply with the study protocol procedures.

   - Consent to collection of previously obtained, archival biopsy or surgical specimens of
   the currently treated malignancy when available.

Exclusion Criteria:

   - Significant cardiac disease.

   - Eye trauma or disease.

   - Ocular surgery or blunt force trauma to the eye requiring treatment within 3 months
   prior to first dose of HGS1036.

   - Presence or history of ≥ Grade 2 hemoptysis within 2 weeks of the first dose of
   HGS1036.

   - Major surgery within 4 weeks of the first dose of HGS1036.

   - Prior organ or allogeneic stem cell transplant.

   - Non-healing or chronic wounds.

   - Receipt of any anti-cancer therapy within 4 weeks prior to first dose of HGS1036.

   - Receipt of any biological therapy (such as monoclonal antibodies) within 6 weeks of
   the first dose of HGS1036.

   - Active CNS involvement by primary or metastatic tumor.

   - Documented active infection requiring the use of systemic antibiotics.

   - Pregnancy or lactation.

   - Known HIV-positive serology, AIDS, or an AIDS-related illness.

   - Conditions likely to increase the potential for abdominal perforation or fistula
   formation.